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ABSTRACT 
The aim of the current investigation is to develop a sustained-release dry powder inhalation 
(DPI) formulation through continuous Hot Melt Extrusion (HME) process and see the impact of 
Sodium Bicarbonate (SB) and Mannitol (MAN) on the hydrophobic Eudragit RL PO (ERLPO) 
polymer. Ball milling and air-jet milling were utilized to have powder with a particle size range 
that is required for inhalation. Air-jet milled formulations showed promising particle size results 
compared to ball milled formulations. All solid-state characterization studies revealed no change 
on Theophylline (TH) crystallinity or occurrence of drug-excipient interactions in physical 
mixtures and formulations. X2 formulation released TH constantly over six hours and has an 
acceptable particle size range for a DPI, therefore, it was chosen as the best formulation. Due to 
the pores that created by SB during HME extrusion, X1 released about half of TH after 15 minutes 
and reached the maximum release on the eighth hour, nevertheless, its particles size was not 
appropriate for DPI. X3 had the most suitable particle size range for a DPI, however, it had no a 
sustained-release behavior and its release was the same as a pure TH. For future studies, X2 will 
be further investigated on Anderson Cascade impaction (ACI), a study that mimic the lung, and 
in-vivo study will be considered based on the ACI result.  
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1. INTRODUCTION 
The local drug delivery approach has been concern of researchers over decades especially 
the pulmonary drug delivery as a dry powder inhaler (DPI) [1]–[4]. Many researchers explored 
this new route to treat many local diseases such as respiratory infection, Tuberculosis and Cystic 
fibrosis, also administering Cyclosporine as an immune suppressive drug or Ibuprofen as a non-
steroidal anti-inflammatory agent [4]–[8]. High bioavailability, fast onset of action, bypass liver 
metabolism, and absence of breath actuation and propellant have made DPI the most preferred 
lung formulation [3], [9]. On the other hand, the lung has a limited volume and that would be a 
problem for water-insoluble drugs, thus a water-soluble drug, Theophylline (TH), was chosen to 
be the model drug on this investigation due to its moderate solubility in water, which is 7.36 mg 
ml-1 [10]. 
Theophylline (Figure 1) is a bronchodilator and has efficiency for treating asthma and 
chronic obstruction pulmonary disorder (COPD) [11]. Also, Barnes reported that at low doses in 
asthma and COPD diseases, TH shows immunomodulatory actions and Fredholm also noticed that 
theophylline improved corticosteroids anti-inflammatory property [12], [13]. However, TH has a 
narrow therapeutic window and adverse reactions on gastrointestinal and cardiovascular systems, 
therefore, preparing TH as an oral sustained-release tablet (as in the market right now) or a DPI 
formulation would help to minimize these problems [14], [15]. Moreover, M. Malamatari et al., 
A. Alhalaweh et al., reported the crystallinity behavior of TH during the spray drying by different 
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solid-state characterization (thermal and non-thermal) methods and stated that TH tends to 
preserve its crystallinity even during the exposure to a high temperature [16], [17]. 
Hot-melt extrusion (HME) has gained a popularity among the pharmaceutical applications 
over the past forty years due to the ability to produce several versatile formulations. HME’s ability 
derived from its advantages over the traditional pharmaceutical processing techniques which are 
including, but not limited to, continuous operation, solvent-free method, few processing steps, low 
cost, and the possibility for industrial scale-up [18], [19]. 
A fine solid crystal suspension (FSCS) is a term has been used recently by L. Lin et al. 
which combines two different techniques to produce a fine crystalline powder to be used as DPI 
[20]. The first technique was using HME to produce a solid crystal suspension (SCS) which the 
crystalline drug suspends in the crystalline excipient. This method showed a good physical stability 
and low hygroscopicity [21], [22]. The other one was using the air-jet milling technique to produce 
a fine particle size powder to be used for inhalation [20]. 
Mannitol (MAN) was chosen to play an important role in formulations and its 
concentration will be dominant to produce SCS while formulations were extruded and to improve 
the milling efficiency for having FSCS formulations. In addition, the good flow property of 
mannitol would improve the aerosolization performance of formulations and increase the drug 
release inside the lung after being mixed with the lung fluids due to its ability as a pore former 
[23], [24]. 
Eudragit® RL PO (ERLPO) has been used commonly in HME process. Due to its 
quaternary ammonium groups that act as salts, the permeability of this hydrophobic copolymer 
toward dissolution media increased and that makes it a good candidate to be in the sustained-
release formulations [25]–[28].    
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The aims of this study were investigating the feasibility to produce FSCS formulations 
using the HME and two dry milling techniques (a ball milling and an air-jet milling) to get a DPI, 
studying the release profile of polymeric and non-polymeric FSCS formulations, and the 
possibility of producing light and porous particles using Sodium Bicarbonate (SB) during the HME 
process. Many reports used a polymer to produce a sustained-release powder for DPI by different 
processing techniques, therefore, Eudragit® RL PO (ERLPO) was utilized in some formulations 
by different concentrations to investigate if there is a release difference inside the limited lung 
fluids.  
 
Figure 1: Theophylline Structure 
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2. MATERIALS AND METHODS  
2.1. Materials 
Anhydrous theophylline (TH) was purchased from Acros Organic (Thermo Fisher 
Scientific, NJ, USA). Pearlitol® 160 C (Mannitol) MAN was obtained as a gift sample from 
Roquette (1417 Exchange Street, P.O. Box 6647, Keokuk, IA 52632). Eudragit® RL PO 
(ERLPO)was kindly gifted by Evonik industries (Piscataway, USA). Sodium bicarbonate (SB) 
was purchased from Fisher Scientific (Hanover Park, IL, USA). 
 
2.2. Methods 
2.2.1. Hot Melt Extrusion 
The active pharmaceutical ingredient at different drug loads was mixed with ERLPO, SB 
and MAN (Table 1) using a V-shell blender (MaxiBlendTM, GlobePharma, North Brunswick, NJ, 
USA) at 25 rpm for 15 min. The physical mixtures were extruded successfully using a co-rotating 
twin-screw extruder (11 mm Process 11™, Thermo Fischer Scientific, Karlsruhe, Germany) with 
standard screw design (Figure 2).  
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Figure 2: HME standard screw design 
2.2.2. Preparing the DPI formulation 
DPI formulations were prepared using two dry milling techniques. The first one was ball 
milling using (Mixer Mill MM400, Retsch GmbH & Co. Germany). 5 mg of each extruded 
formulation was placed in a 25-ml stainless steel milling jar and accompanied by 3 stainless steel 
balls (6 mm diameter each). The extrudates were milled for 30 min at 30-Hz oscillations. The 
second technique was using air-jet milling (Model 00 Jet-O-MizerTM also known as Aljet mill, 
Fluid Energy, Telford, PA, USA).  
 
2.2.3. Differential Scanning Calorimetry (DSC) 
 The thermal behavior of TH, ERLPO, and other excipients was studied by DSC 25, TA 
Instrument which was calibrated with indium. Samples (4–5 mg) were crimped in standard 
aluminum pans and sealed with the standard aluminum lid. After that, they were heated and 
scanned from 30 to 300℃ at a heating rate of 20℃ /min under a flow rate of 50ml/min of dry 
nitrogen atmosphere. An empty aluminum pan was placed as a reference.  
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2.2.4. Power X-ray Diffraction (PXRD): 
PXRD was performed using a Bruker D8 Advance (Bruker, Billerica, MA, USA) with a 
Cu-source and theta-2theta diffractometer equipped with a Lynx-eye Position Sensitive Detector. 
The generator was set to a voltage of 40 kV and a current of 30 mA. The samples were dispersed 
on a low background Si sample holder and compacted gently with the back of a metal spatula. The 
scan ran from 5° to 40° 2θ with a 0.05 step size at 3 s/step.  
 
2.2.5. Fourier Transform Infrared Spectroscopy (FT-IR)   
 FTIR analysis was conducted in the spectral range of 4000–650cm-1 using Cary 660 and 
Cary 620 FTIR Microscopes (Agilent Technologies, Santa Clara, CA, USA). The bench was 
equipped with a MIRacle ATR (Pike Technologies, Fitchburg, WI, USA), that was fitted with a 
single bounce, diamond-coated ZnSe internal reflection element. FT-IR was performed to 
determine molecular interactions of pure TH and in the presence of SB, MAN and ERLPO in the 
formulations before and after applying high shear forces and elevated temperatures. 
 
Table 1: Formulations composition, HME process parameters, and drug content 
 
 
 
 
Formulations TH 
% 
MAN 
% 
ERLPO 
% 
SB 
% 
Temperature     
°C 
Screw speed 
(rpm) 
Drug Content 
(%) 
X1 30 40 25 5 160 150 99.8±0.4 
X2 20 60 20 0 160 200 100.6±0.1 
X3 20 80 0 0 160 200 100.2±0.2 
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2.2.6. Powder density and flow properties  
The flowability of formulations was determined by measuring the bulk and tapped densities 
to calculate Carr’s index (CI) and Hausner ratio (HR) (Table 2). The powder of each formulation 
was placed into a 25-mL measuring cylinder and the bulk volume was recorded, then the cylinder 
was tapped 100 taps manually and the new tapped volume was noted[14]. Based on preliminary 
experiments, 100 taps were enough to reach the maximum powder reduction. Then Carr’s Index 
and Hausner ratio were calculated using the following equations: 
 𝐶𝐼 = (
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦−bulk density
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
)  ×  100               𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑟𝑎𝑡𝑖𝑜 =  
𝑡𝑎𝑝 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
  
 
Table 2: Formulation densities, Carr’s index, Hausner ratio, and moisture content
 
 
2.2.7. Scanning Electron Microscopy (SEM) 
The samples were placed on aluminum stubs held with a carbon adhesive film. Gold was 
used to coat the samples by a Hummer 6.2 sputtering system (Anatech Ltd., Battlecreek, MI, USA) 
in a high-vacuum evaporator. The surface morphology of every sample was analyzed by a scanning 
electron microscope (SEM) operating at an accelerating voltage from 1.0 kV to 5.0 kV (JEOL 
JSM-5600; JEOL, Inc., Peabody, MA, USA). FIJI/Image J software was used to record the pore 
diameter and study the impact of SB on pore formation before and after the milling process.  
 
Formulation Bulk Density 
(g/cm3) 
Tapped Density 
(g/cm3) 
CI 
(%) 
HR Moisture content 
(%) 
X1 0.34±0.04 0.46±0.03 25 1.33 2.49 
X2 0.32±0.02 0.41±0.03 22.2 1.28 0.7 
X3 0.3±0.01 0.36±0.02 16.6 1.2 0.68 
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2.2.8. Moisture Content 
Moisture content was studied by evaluating loss on drying (LOD) using a halogen moisture 
analyzer balance (MB45 moisture analyzer, Ohaus, USA). The percentage of moisture was 
estimated by drying 1-2 g of each formulation at 105 °C for 10 min (Table 2). 
 
2.2.9. HPLC Analysis 
Quantitative high-performance liquid chromatography (HPLC) was used as mentioned in 
USP 38 with an isocratic mode of elution (Waters Corp., Milford, MA, USA) equipped with an 
autosampler, UV/VIS detector and Empower software. The column was a reverse phase XTerra® 
C18 (5µm, 150 mm x 4.6 mm) was used to analyze theophylline at 280 nm wavelength. The 
mobile phase consisted of 92:7:1 % (v/v/v) of 0.01M sodium acetate trihydrate buffer: acetonitrile: 
glacial acetic acid pumped at a flow rate of 1 mL/min and the injection volume was 10µL. The 
samples were filtered using a 0.22µm filter (Millex® GV, Durapore® PVDF).  
 
2.2.10.  Drug Content 
An amount, that has 50 mg of TH, of each extruded formulation was dissolved in 50 ml 
water and TH concentrations were detected by HPLC system as mentioned previously on HPLC 
analysis section. The correlation coefficient of the calibration curve was 0.999 over a concentration 
range of 1-225 µg ml-1  
 
2.2.11.  Particle size distribution (PSD) by laser light diffraction  
PSDs were determined using a Sympatec Helos equipped with a Cuvette module (System-
Partikel-Technik GmbH, Clausthal-Zel-lerfeld, Germany). Data were analyzed using the 
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Sympatec WINDOX software. The particle size distribution of each air-jet milled formulation was 
measured and particle diameters at the 10th (D10), 50th (D50), and 90th (D90) percentile were 
observed and used to calculate the span by the following equation: Span=(d90-d10)/d50). A lower 
span means a narrow size distribution (Table 3). 
 
2.2.12.  Drug release-study 
Dissolution was performed for the extruded DPI formulations in phosphate-buffered saline 
(1 mL, pH 7.4) in dialysis bag and then placed into the phosphate buffer dissolution medium 
(37±0.5 °C, 100 rpm) using a dialysis bag with a molecular weight cut-off of 20,000 Da. To 
accomplish the sink conditions and the saturation solubility of TH, 300 mL of dissolution media 
was used and an exact amount was compensated during every sample withdrawn. The samples 
were withdrawn at predetermined time intervals over eight hours. The samples were suitably 
diluted and analyzed for theophylline content by UV spectrophotometry at 274nm wavelength[14]. 
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3. RESULTS AND DISCUSSION 
3.1. Solid State Characterization 
3.1.1. DSC 
The thermal behavior of TH, MAN, ERLPO, and SB was analyzed by DSC. The pure TH 
endothermic peak was observed at 275℃ (Figure 3). The DSC results revealed the crystalline 
nature of TH in the extrudates and other excipients thermal stability during HME at the extrusion 
temperature (160℃), but PXRD is required to proof the crystallinity of TH. Ball and air-jet milling 
had no effect on the status of extruded formulations especially the crystallinity of MAN which was 
seen and noticed after the HME. The TH melting peak showed a change in its thermal behavior in 
the presence of MAN (Figure 4), it disappeared before and after the HME process, which is 
probably explained by the hypothesis that it dissolved in the MAN during extrusion [16]. MAN’s 
endothermic peak was sharp and seen at 170℃ in physical mixtures or extrudates.  
 
Figure 3: DSC thermal curves of pure TH, MAN, ERLPO, SB, and physical mixture
Overlay
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Figure 4: DSC thermal curves of physical mixtures and extruded formulations 
 
3.1.2.  PXRD 
PXRD studies of pure TH and formulation showed the presence of all characteristic peaks 
of TH, thus, TH retained its crystalline nature after the exposure to a high temperature during the 
HME process (Figure 5).  
 
 
Figure 5: PXRD of pure TH and formulations 
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3.1.3. FT-IR 
 TH showed prominent wavenumbers at 1704, 1659, and 1560 cm-1 [29]. At the first two 
wavenumbers, FTIR revealed the presence of C=O stretching vibration of carbonyl groups and the 
stretching vibration of imine group at 1566 cm-1 of TH (Figure 1) and other excipients peaks in 
physical mixtures and all extruded formulations (Figure 6, Figure 7, and Figure 8) suggesting no 
interaction occurred. 
 
Figure 6: FT-IR results of X1 
 
Figure 7: FT-IR results of X2 
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Figure 8: FT-IR results of X3 
3.2. Characterization of Morphology and Particle size 
3.2.1. SEM 
A cross-sectional area of the extrudates was examined by SEM to see the effect of HME 
process and incorporation of Sodium Bicarbonate as a pore former. Figure 9 shows the image of 
formulation X1 and the resulted pores. The pores were varied in size and shape which may be an 
indication of places were SB distributed mostly inside formulations. On the preliminary study, it 
was noticed that incorporation of MAN led to enhance the screw speed performance which resulted 
in decreasing the residence time of formulations inside the HME and that led to decrease in the 
number of pores. SB did not get the efficient time to transfer into Sodium Carbonate and release 
all CO2. Furthermore, MAN helped to improve the torque situation during the process as its 
concentration in formulations increases and that because of its good flow property. 
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Figure 9: The SEM image of extrudate with Sodium Bicarbonate as a pore former 
 
 
Figure 10: SEM images of ball milled formulations 
The particle size and morphology of powder would have an influence on the dry powder 
inhaler performance in the lung [30]. Alhalaweh et al. and M. Malamatari et al. pictured starting 
materials of Theophylline and mannitol by SEM and they described their shapes as needle-shaped 
particles and elongated particles, respectively [16], [17]. During the HME, materials liquefied, and 
final product was strands. The milling micronized these strands into a powder which were shaped 
differently than its origin as in Figure 10. 
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Figure 10 showed the formulations after micronized by the ball milling. Particles size 
differed from formulation to another and the range was approximately about 2-50µm. Also, it was 
noticed that as mannitol amount increased in the formulation the particle size decreased. Therefore, 
this change in size reduction supports the hypothesis that mannitol has a co-milling ability [31], 
[32].  
 
 Table 3: PSD parameters 
 
3.2.2. PSD 
The particle size distribution would be a key factor study on determining which is the 
efficient milling method in our study. The D50 and D90 of each formulation give an impression and 
a slight prediction about formulations’ behavior on the Anderson cascade impaction (ACI) study 
which is considered a mimic for the lung system. The span of each formulation was a small number 
and that illustrates the narrow particle size distribution which means most particles were around 
the size of D50. X1 showed particles with bigger size than other formulations and that may be due 
to the low percentage of MAN in it, but its result was considered a better than the ball milling 
result when compare between them. X2 and X3 showed promising results especially when 
focusing on the D50 which tells that the outcome percentages of half of the two formulations were 
within or near the acceptable range of DPI. Furthermore, X3 might be the promising formulation 
as a DPI due to its particles size which most of them were around the 6 µm. 
 
Formulation D10 (µm) D50 (µm) D90 (µm) Span 
X1 12.77 34.25 45.39 0.9 
X2 8.75 13.48 26.42 1.3 
X3 5.57 6.25 11.16 0.8 
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3.3. Moisture Content: 
X1 formulation was observed to absorb moisture more than other formulations and that 
related to sodium bicarbonate which has a hygroscopic nature [33], [34]. X2 has a water insoluble 
polymer and mannitol, which is only in X3, that has no a moisture uptake even at high relative 
humidity[35]. 
 
3.4. Drug release-study 
The formulations (X1 and X2) were expected to have a sustained-release behavior due to 
the presence of ERLPO, but the X3 was not (Table 1). X1 and X2 showed a variation on releasing 
TH at the first time point and that might be related to the low ERLPO’s percentages that let TH 
dispersed incompletely inside their matrix (Figure 11). Therefore, some TH dissolved in mannitol 
and others dispersed on ERLPO. Furthermore, X1 exhibited a faster release on the first time point 
than other formulation by releasing 50% of TH and that could be the effect of pores which were 
generated by SB during the HME process. X2 showed the lowest release of TH content after 15 
minutes among other formulations and reached its maximum release on the sixth hour. X3 and a 
pure TH were expected to behave in the same way and they were almost the same.  
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Figure 11: The release-study of all formulations 
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